Evaluation of the effects of omega-3 fatty acids for biomarkers of idiopathic interstitial pneumonias (IIPs) with hypertriglyceridemia
Not Applicable
- Conditions
- Idiopathic interstitial pneumonias
- Registration Number
- JPRN-UMIN000024260
- Lead Sponsor
- Graduate School of Medicine, Nippon Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
(1)A pregnant woman or the woman who may be pregnant. (2)Patients who have received immunosuppressants (e.g. Ciclosporin or Cyclophosphamide), pirfenidone, or N-acetylcysteine within 6 months prior to participation. (3)Patients who began oral corticosteroids therapy within 6 months prior to participation. Patients who have received high-dose corticosteroids (>10 mg prednisolone daily) (4)Patients taking DHA or EPA within 3 months prior to participation (5)Patients with unstable IIPs. (6)Patients with severe anemia, liver disease, renal disease, heart disease or bleeding. (7)In addition, the patients who are not eligible for participation judged by a doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of the biomarkers of IIPs
- Secondary Outcome Measures
Name Time Method